CytRx Corp. (CYTR)

0.60
NASDAQ : Health Technology
Prev Close 0.60
Day Low/High 0.59 / 0.61
52 Wk Low/High 0.33 / 2.18
Avg Volume 137.80K
Exchange NASDAQ
Shares Outstanding 33.64M
Market Cap 20.10M
EPS -1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
CytRx Initiates Phase 2 Clinical Trial With INNO-206 In Pancreatic Cancer

CytRx Initiates Phase 2 Clinical Trial With INNO-206 In Pancreatic Cancer

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients...

CytRx Receives NASDAQ Extension

CytRx Receives NASDAQ Extension

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it has received a favorable ruling from the NASDAQ Hearings Panel (the “Panel”), whereby the...

CytRx Announces Issuance Of Key U.S. Patent Covering INNO-206 Linker Technology

CytRx Announces Issuance Of Key U.S. Patent Covering INNO-206 Linker Technology

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that the U.

CytRx’s INNO-206 To Be Featured In Two Presentations At The American Association For Cancer Research (AACR) 2012 Annual Meeting

CytRx’s INNO-206 To Be Featured In Two Presentations At The American Association For Cancer Research (AACR) 2012 Annual Meeting

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced the upcoming presentation of research demonstrating that INNO-206 in combination with either doxorubicin or a ...

CytRx Reports 2011 Financial Results

CytRx Reports 2011 Financial Results

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the 12 months ended December 31, 2011, and provided a business update.

CytRx To Present At The Roth Capital Partners Annual OC Growth Stock Conference

CytRx To Present At The Roth Capital Partners Annual OC Growth Stock Conference

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that President and Chief Executive Officer Steven A.

CytRx To Present At The 2012 Cowen & Company Health Care Conference

CytRx To Present At The 2012 Cowen & Company Health Care Conference

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that Vice President of Business Development David J.

CytRx Receives Notification Of Non-Compliance With NASDAQ Minimum Bid Requirement

CytRx Receives Notification Of Non-Compliance With NASDAQ Minimum Bid Requirement

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company specializing in oncology, today announced that, as anticipated, on February 15, 2012, the Company was notified by The NASDAQ Stock Market that because the...

CytRx To Present At BIO CEO & Investor Conference

CytRx To Present At BIO CEO & Investor Conference

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced that President and Chief Executive Officer Steven A.

CytRx Initiates International Phase 2b Clinical Trial With INNO-206 In Advanced Soft Tissue Sarcoma

CytRx Initiates International Phase 2b Clinical Trial With INNO-206 In Advanced Soft Tissue Sarcoma

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced the initiation of an international Phase 2b clinical trial to evaluate the preliminary efficacy and safety of its...

CytRx Announces The Presentation Of Favorable Phase 2 Clinical Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia At ASH Conference

CytRx Announces The Presentation Of Favorable Phase 2 Clinical Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia At ASH Conference

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that results from the open-label, single-agent Phase 2 ENABLE proof-of-concept clinical trial demonstrate...

5 Stocks Under $10 With Big Upside Potential

5 Stocks Under $10 With Big Upside Potential

Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.

CytRx Reports Third Quarter 2011 Financial Results

CytRx Reports Third Quarter 2011 Financial Results

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the three months and nine months ended September 30, 2011, and provided a business update.

CytRx To Present At Lazard Capital Markets 8th Annual Healthcare Conference

CytRx To Present At Lazard Capital Markets 8th Annual Healthcare Conference

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that President and Chief Executive Officer Steven A.

CytRx Announces Favorable Initial Results From Its Ongoing Phase 1b/2 Clinical Trial In Patients With Soft Tissue Sarcomas

CytRx Announces Favorable Initial Results From Its Ongoing Phase 1b/2 Clinical Trial In Patients With Soft Tissue Sarcomas

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft...

CytRx’s ENABLE Phase 2 Trial Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia To Be Presented At The Prestigious 53rd Annual ASH Meeting

CytRx’s ENABLE Phase 2 Trial Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia To Be Presented At The Prestigious 53rd Annual ASH Meeting

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that an abstract with results from the Company’s ENABLE Phase 2 proof-of-concept clinical trial with its...

CytRx To Substantially Increase Patient Enrollment In INNO-206 Phase 1b/2 Clinical Trial Principally In Patients With Soft Tissue Sarcomas

CytRx To Substantially Increase Patient Enrollment In INNO-206 Phase 1b/2 Clinical Trial Principally In Patients With Soft Tissue Sarcomas

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it is tripling the number of patients in its Phase 1b/2 clinical trial who will be treated with its...

CytRx To Present At The Rodman & Renshaw 13th Annual Healthcare Conference

CytRx To Present At The Rodman & Renshaw 13th Annual Healthcare Conference

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, announced that David Haen, the Company’s Vice President of Business Development, will present at the Rodman & Renshaw ...

CytRx President And CEO Steven Kriegsman And CMO Dr. Daniel Levitt Discuss Company Advantages And Oncology Clinical Pipeline Attributes In OncLive Interview

CytRx President And CEO Steven Kriegsman And CMO Dr. Daniel Levitt Discuss Company Advantages And Oncology Clinical Pipeline Attributes In OncLive Interview

CytRx Corporation (Nasdaq:CYTR) President and CEO Steven A. Kriegsman and Chief Medical Officer Daniel Levitt, MD, Ph.

CytRx Reports Second Quarter 2011 Financial Results

CytRx Reports Second Quarter 2011 Financial Results

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the three months and six months ended June 30, 2011, and provided a business update.

CytRx’s INNO-206 In Combination Therapy Induces Complete Remissions In Aggressively Growing Ovarian Cancer Tumor Model

CytRx’s INNO-206 In Combination Therapy Induces Complete Remissions In Aggressively Growing Ovarian Cancer Tumor Model

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced the achievement of complete remissions in aggressively growing in vivo ovarian cancer tumors treated with a...

CytRx Prices $20.4 Million Public Offering

CytRx Prices $20.4 Million Public Offering

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it has priced an underwritten public offering of 39,200,000 shares of common stock and warrants to purchase...

CytRx Announces Public Offering

CytRx Announces Public Offering

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it intends to offer shares of its common stock and common stock purchase warrants in an underwritten public...

CytRx Announces Safe Administration Of High Doses Of Doxorubicin With Its Tumor-Targeted Drug, INNO-206

CytRx Announces Safe Administration Of High Doses Of Doxorubicin With Its Tumor-Targeted Drug, INNO-206

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that its tumor-targeted doxorubicin conjugate, INNO-206, is delivering doxorubicin safely at doses over 4 times...

CytRx Receives FDA Orphan Drug Designation For INNO-206 For The Treatment Of Soft Tissue Sarcomas

CytRx Receives FDA Orphan Drug Designation For INNO-206 For The Treatment Of Soft Tissue Sarcomas

CytRx Corporation (Nasdaq: CYTR), a biotechnology company specializing in oncology, today announced that the Office of Orphan Product Development of the U.

CytRx Reports Positive Preliminary Results From ENABLE Phase 2 Clinical Trial With Bafetinib In Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

CytRx Reports Positive Preliminary Results From ENABLE Phase 2 Clinical Trial With Bafetinib In Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the...

CytRx Completes Sale Of Molecular Chaperone Assets To Orphazyme ApS In Deal Worth Up To $120 Million

CytRx Completes Sale Of Molecular Chaperone Assets To Orphazyme ApS In Deal Worth Up To $120 Million

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that it has sold the worldwide rights to its molecular chaperone assets to privately-held, Copenhagen, ...

CytRx Reports First Quarter 2011 Financial Results

CytRx Reports First Quarter 2011 Financial Results

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today reported financial results for the three months ended March 31, 2011, and provided a business update.

CytRx’s INNO-206 Receives FDA Approval For Orphan Drug Designation For Pancreatic Cancer

CytRx’s INNO-206 Receives FDA Approval For Orphan Drug Designation For Pancreatic Cancer

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical company specializing in oncology, today announced that its tumor-targeting pro-drug candidate INNO-206 has been approved for orphan drug designation for the...

CytRx Increases Clinical Sites To 15 In Tamibarotene Phase 2b Clinical Trial In 1st Line Non-Small-Cell Lung Cancer To Expedite Patient Recruitment

CytRx Increases Clinical Sites To 15 In Tamibarotene Phase 2b Clinical Trial In 1st Line Non-Small-Cell Lung Cancer To Expedite Patient Recruitment

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, has expanded enrollment to 15 clinical sites in its Phase 2b clinical trial with tamibarotene in combination with ...

TheStreet Quant Rating: D- (Sell)